Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global, randomized, pivotal Phase III clinical trial of tislelizumab for the treatment of gastric cancer and oesophageal cancer

Trial Profile

A global, randomized, pivotal Phase III clinical trial of tislelizumab for the treatment of gastric cancer and oesophageal cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 21 Nov 2018 New trial record
    • 07 Nov 2018 According to a Beigene media release, the company plans to initiate this trial in 2018 or early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top